Abstract
Purpose: FIAU, (1-(2′-deoxy-2′-fluoro-1-β-D- arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18F-FAU. Methods: CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18F-FIAU or 18F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min post-injection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. Results: Biodistribution and imaging studies showed the highest uptake of 18F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07±0.40 and 6.15±1.58 and that of MH3924A tumors were 0.19±0.07 and 0.47±0.06 at 60 and 150 min, respectively. In 18F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18F-FAU. Imaging and biodistribution studies with 18F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. Conclusion: 18F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors. 18F-FAU does not show any preferential accumulation in HSV-TK expressing tumors. In the 18F-FIAU treated mice, the 18F-FAU contribution to the total uptake seen in HSV-TK positive tumors is minimal.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1987-1993 |
| Number of pages | 7 |
| Journal | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2009 |
| Externally published | Yes |
Fingerprint
Keywords
- F
- FIAU
- Gene expression
- HSV-TK
- Metabolism
- PET imaging
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Herpes simplex virus thymidine kinase imaging in mice with (1-(2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl)- 5-iodouracil) and metabolite (1-(2′-deoxy-2′-[18F]fluoro- 1-β-D-arabinofuranosyl)-5-uracil). / Nimmagadda, Sridhar; Mangner, Thomas J.; Lawhorn-Crews, Jawana M.; Haberkorn, Uwe; Shields, Anthony F.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 12, 12.2009, p. 1987-1993.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Herpes simplex virus thymidine kinase imaging in mice with (1-(2′-deoxy-2′-[18F]fluoro-1-β-D-arabinofuranosyl)- 5-iodouracil) and metabolite (1-(2′-deoxy-2′-[18F]fluoro- 1-β-D-arabinofuranosyl)-5-uracil)
AU - Nimmagadda, Sridhar
AU - Mangner, Thomas J.
AU - Lawhorn-Crews, Jawana M.
AU - Haberkorn, Uwe
AU - Shields, Anthony F.
PY - 2009/12
Y1 - 2009/12
N2 - Purpose: FIAU, (1-(2′-deoxy-2′-fluoro-1-β-D- arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18F-FAU. Methods: CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18F-FIAU or 18F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min post-injection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. Results: Biodistribution and imaging studies showed the highest uptake of 18F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07±0.40 and 6.15±1.58 and that of MH3924A tumors were 0.19±0.07 and 0.47±0.06 at 60 and 150 min, respectively. In 18F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18F-FAU. Imaging and biodistribution studies with 18F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. Conclusion: 18F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors. 18F-FAU does not show any preferential accumulation in HSV-TK expressing tumors. In the 18F-FIAU treated mice, the 18F-FAU contribution to the total uptake seen in HSV-TK positive tumors is minimal.
AB - Purpose: FIAU, (1-(2′-deoxy-2′-fluoro-1-β-D- arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18F-FAU. Methods: CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18F-FIAU or 18F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min post-injection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. Results: Biodistribution and imaging studies showed the highest uptake of 18F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07±0.40 and 6.15±1.58 and that of MH3924A tumors were 0.19±0.07 and 0.47±0.06 at 60 and 150 min, respectively. In 18F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18F-FAU. Imaging and biodistribution studies with 18F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. Conclusion: 18F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors. 18F-FAU does not show any preferential accumulation in HSV-TK expressing tumors. In the 18F-FIAU treated mice, the 18F-FAU contribution to the total uptake seen in HSV-TK positive tumors is minimal.
KW - F
KW - FIAU
KW - Gene expression
KW - HSV-TK
KW - Metabolism
KW - PET imaging
UR - http://www.scopus.com/inward/record.url?scp=71849100449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71849100449&partnerID=8YFLogxK
U2 - 10.1007/s00259-009-1177-y
DO - 10.1007/s00259-009-1177-y
M3 - Article
C2 - 19506865
AN - SCOPUS:71849100449
VL - 36
SP - 1987
EP - 1993
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
SN - 1619-7070
IS - 12
ER -